At a glance
ClinicalIndex Comparison RecordPhase 2Completed· 121 enrolled
Drug / intervention
PXL770 +1 moredrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A Randomized, Double-blind, Placebo-controlled, Parallel Group Trial to Assess the Efficacy and Safety of PXL770 Versus Placebo After 12 Weeks of Treatment in Patients With NAFLD
In Brief
A Phase 2 clinical trial evaluating PXL770 and Placebo Oral Capsule for Nonalcoholic Fatty Liver. Completed, enrolled 121 participants across 15 sites.
Detailed Summary
This study will assess the efficacy and safety of 3 doses of PXL770 versus placebo after 12 weeks of treatment.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsNonalcoholic Fatty Liver
CountriesUnited States
Collaborators--
Timeline
Phase 2CompletedFinished
20192020202120222023202420252026
First PostedDec 2018
Enrollment StartMar 2019
Primary CompletionAug 2020
Study CompletionAug 2020
TodayJul 2026
First PostedDec 4, 2018
Enrollment StartMar 29, 2019
Primary CompletionAug 3, 2020
Study CompletionAug 10, 2020
TodayJul 2, 2026
Enrollment to primary: 1.3 yearsPosted 7.6 years ago
Interventions
PXL770drug
Oral capsule
Placebo Oral Capsuledrug
Oral capsule